Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IP6K1 | Q92551 | 1/20 | 0.45 |
| ▸ | TNKS | O95271 | 7/20 | 0.43 |
| ▸ | PARP1 | P09874 | 7/20 | 0.43 |
| ▸ | TNKS2 | Q9H2K2 | 7/20 | 0.43 |
| ▸ | GUSB | P08236 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 3/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30434323 | 1.00 | IP6K1 (0.45) | IP6K1TNKSPARP1TNKS2GUSB | |
| SCHEMBL146211 | 0.89 | IP6K1 (0.44) | IP6K1TNKSPARP1TNKS2GUSB | |
| SCHEMBL30435023 | 0.89 | IP6K1 (0.44) | IP6K1TNKSPARP1TNKS2GUSB | |
| SCHEMBL148227 | 0.82 | TNKS (0.50) | TNKSPARP1TNKS2GUSBNPC1 | |
| SCHEMBL147895 | 0.82 | TNKS (0.50) | TNKSPARP1TNKS2GUSBNPC1 | |
| SCHEMBL347973 | 0.78 | TNKS (0.54) | TNKSPARP1TNKS2GUSBNPC1 | |
| SCHEMBL148469 | 0.77 | ALDH1A1 (0.50) | NPC1RAB9A | |
| SCHEMBL28017671 | 0.77 | IP6K1 (0.71) | IP6K1PARP1TNKS2NPC1RAB9A | |
| SCHEMBL120728 | 0.75 | ALDH1A1 (0.44) | TNKSPARP1TNKS2GUSBNPC1 | |
| SCHEMBL30434826 | 0.75 | ALDH1A1 (0.44) | TNKSPARP1TNKS2GUSBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107252429-B | Novel anti-inflammatory agent | 雷斯韦洛吉克斯公司 | 2023-06-16 | — | — | CN | disclosed |
| EP-3431086-B1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP (CA) | 2020-06-17 | — | — | EP | disclosed |
| US-20200129512-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2020-04-30 | — | — | US | disclosed |
| EP-3431086-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | Resverlogix Corp. (CA) | 2019-01-23 | — | — | EP | disclosed |
| EP-2421533-B1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP (CA) | 2018-10-17 | — | — | EP | disclosed |
| US-20170333419-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2017-11-23 | — | — | US | disclosed |
| US-20170326143-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2017-11-16 | — | — | US | disclosed |
| US-9757368-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2017-09-12 | — | — | US | disclosed |
| CN-102458405-B | Novel anti-inflammatory agents | 雷斯韦洛吉克斯公司 | 2017-06-23 | — | — | CN | disclosed |
| WO-2013186612-A1 | THE USE OF SUBSTITUTED 2-PHENYL-3H-QUINAZOLIN-4-ONES AND ANALOGS FOR INHIBITING BET (BROMODOMAIN AND EXTRA TERMINAL DOMAIN) PROTEINS | RVX THERAPEUTICS INC. (CA) | 2013-12-19 | — | — | WO | disclosed |
| US-20130281398-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | disclosed |
| CN-102458405-A | Novel anti-inflammatory agents | RESVERLOGIX CORP | 2012-05-16 | — | — | CN | disclosed |
| US-20120059002-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2012-03-08 | — | — | US | disclosed |
| EP-2421533-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010123975-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059002-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | IP6K1 538/4885TNKS 723/4885PARP1 901/4885 |
| US-20130281398-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | PHKB, BAZ2A, EP300 | IP6K1 1255/4885TNKS 644/4885PARP1 332/4885 |
| US-20170326143-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | IP6K1 538/4885TNKS 723/4885PARP1 901/4885 |
| US-20170333419-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | IP6K1 538/4885TNKS 723/4885PARP1 901/4885 |
| US-20200129512-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | IP6K1 538/4885TNKS 723/4885PARP1 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.